Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8815519 | Journal of Affective Disorders | 2018 | 27 Pages |
Abstract
These results support a potential role for biomarkers involved in neuroprotection and activation of plasticity pathways in lithium's clinical response. Evidence supporting this model comes from results evaluating macroscopic and microscopic brain structure as well neurochemical findings in vivo from cellular to sub-synaptic (molecules and intracellular signaling) compartments using central and peripheral biomarkers. Challenges to precisely decipher lithium's biological mechanisms involved in its therapeutic profile include the complex nature of the illness and clinical subtypes, family history and comorbid conditions. In the context of personalized medicine, it is necessary to validate predictive biomarkers of response to lithium by designing longitudinal clinical studies during mood episodes and associated clinical dimensions in BD.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
Rodrigo Machado-Vieira,